University of Louisville homepage
All experts
All experts

Benjamin Rogers

Assoc Professor Term

School of Medicine

Orcid identifier0000-0002-5322-6375
  • Assoc Professor Term
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 1
Showing page 1, sponsored projects 1 to 23 of 23
GRANT
AWD-00000338|SPY123-201 - Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-Acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Spyre Therapeutics, Inc.4 Jan 2026 - 4 Jan 2031
MORELEARN MORE
GRANT
241126|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to
Merck and Company Inc_MERCKCO2 Jan 2025 - 2 Jan 2030
MORELEARN MORE
GRANT
AWD-00000234 | Vedolizumab-4051: An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD)
Alimentiv Inc_ALI1 Jan 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
AWD-00000251|TAK-279-IBD-2001 - A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib in Participants with Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn’s Disease
Takeda Pharmaceuticals Inc1 Jan 2025
MORELEARN MORE
GRANT
AWD-00000230|Vedolizumab-4054 -An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy with Tofacitinib in Adult Patients with Moderately to Severely Active Ulcerative Colitis”
Takeda Pharmaceuticals Inc_TPI11 Sep 2024
MORELEARN MORE
GRANT
240678|TAK-279-CD-2001 -A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn's Disease
ICON Clinical Research_ICON4 May 2024
MORELEARN MORE
GRANT
240724|TAK-279-UC-2001 - A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Induction, Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Ulcerative Colitis
ICON Clinical Research_ICON1 Jan 2024
MORELEARN MORE
GRANT
230374|TV48574-IMM-20036 - A 14-Week Phase 2b, R, DB, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Sfty, and Tol of TEV-48574 in Adult Pts w Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
IQVIA RDS Inc_IQVIA6 Jul 2023
MORELEARN MORE
GRANT
230195|ABX464-105 -A R, DB, PC MC phase III study to evaluate the efficacy & safety of ABX464 once daily for induction treatment in sub W moderately to severely active ulcerative colitis, Evaluation for Ulcerative Colitis Therapy -1
IQVIA RDS Inc_IQVIA1 Jan 2023
MORELEARN MORE
GRANT
230219|ABX464-107 - A R, DB, MC phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
IQVIA RDS Inc_IQVIA1 Jan 2023
MORELEARN MORE
GRANT
230368|PR2052: PATENT-E: Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Esophagus
Labcorp Drug Development_LABCORP1 Jan 2023 - 31 Dec 2028
MORELEARN MORE
GRANT
230754|CIN-102-123 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics of Oral CIN-102 in Subjects with Diabetic Gastroparesis
Medpace Inc_MPI1 Jan 2023
MORELEARN MORE
GRANT
230758|A0015 - Comparison of the Atmo Motility Gas Capsule System to the reference standard (SmartPill) for gastrointestinal transit time measures in patients with functional gastrointestinal symptoms and dysmotility
Atmo Biosciences Pty Limited_ATMOBIOS1 Jan 2023
MORELEARN MORE
GRANT
240080|TEV48574-IMM-20038 A 24-Week, Ph 2b, R, D-B Long-Term Ext Study to Eval Pharmacokinetics, Eff, Sfty, and Tolerability of TEV-48574 in Adult Pts Moderate to Severe Ulcerative Colitis or Crohn's Disease
IQVIA RDS Inc_IQVIA1 Jan 2023
MORELEARN MORE
GRANT
211055C|U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium
National Institutes of Health_NIH1 Sep 2022 - 31 Jul 2027
MORELEARN MORE
GRANT
211055|U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium
National Institutes of Health_NIH9 Jan 2022
MORELEARN MORE
GRANT
220120|CC-93538-EE-001 -A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in adult and Adolescent Subjects with Eosinophilic Esophagitis
PPD Clinical Research_PCR1 Jan 2022
MORELEARN MORE
GRANT
220823|PCS12852-GP-01 -A Phase 2A PC, R, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Pts w Moderate to Severe Gastroparesis
Medpace Inc_MPI1 Jan 2022
MORELEARN MORE
GRANT
230183|CNTO1959CRD3004 -R, DB, PC, PG, MC Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Parexel International Corporation_PIC1 Jan 2022
MORELEARN MORE
GRANT
230362|PR2053 -Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture-Bowel (PATENT-B)
Labcorp Drug Development_LABCORP1 Jan 2022
MORELEARN MORE
GRANT
210047|02-GI-002 (ECLIPSE) Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Guardant Health Inc_GHI3 May 2021
MORELEARN MORE
GRANT
200598|JHFE Faculty Recruitment-Benjamin Rogers
Jewish Heritage Fund for Excellence_JHFE8 Jan 2020
MORELEARN MORE
GRANT
210394|NG101-201 - A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NG101 Administered Orally to Patients with Gastroparesis
PPD Clinical Research_PCR1 Jan 2020
MORELEARN MORE